Final analysis published from MammoSite Breast Cancer study

The final analysis of the American Society of Breast Surgeons (ASBS) MammoSite Breast Brachytherapy Registry Trial data confirms previous results for the Mammosite targeted radiation therapy system, from Hologic Inc, for treating Breast Cancer, and compares favorably with other forms of accelerated partial breast irradiation (APBI) and with outcomes seen in patients treated with whole breast irradiation with similar follow-up. The final analysis demonstrates low rates of local recurrence, long-term cosmesis of greater than 90% and toxicity rates of less than 10%.

The seven year MammoSite Registry Trial followed over 1,400 patients who were diagnosed with early stage Breast Cancer and underwent breast conserving therapy, which included treatment with the MammoSite system, between May 2002 and June 2004. The analysis is published in the Annals of Surgical Oncology. See: "Treatment Efficacy with Accelerated Partial Breast Irradiation (APBI): Final Analysis of the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial." Shah C et al. Ann Surg Oncol. 2013 Aug 22. PubMed PMID: 23975302